PCI Pharma, a Philadelphia-based CDMO, unveiled plans to expand operations at its Tredegar, Wales, manufacturing operations as part of the company’s push into targeted oncology therapies.
A dollar amount for the project wasn’t disclosed, but the company said that it will add two new facilities focused on manufacturing and packaging solid oral dose tablets and capsules.
A second contained manufacturing building—the first was opened in 2013—will allow PCI to double large-scale processing capacity at the site. The new packaging facility will feature primary and secondary blistering and bottling suites.
The project is expected to create about 40 new jobs in the first year, the company said. PCI, which employs about 500 at the site, has operated the plant for more than four decades.
The announcement comes two months after PCI said it would spend $100 million to expand aseptic liquid fill-finish manufacturing operations at its Bedford, New Hampshire, facility, which it bought from Lyophilization Services of New England in December for an undisclosed price.
“The rapid evolution of oncology pipelines has coincided with the continued globalization of clinical development,” Rebecca Coutts, PCI’s general manager at Tredegar, said in a statement.
About a quarter of all medicines approved by the FDA between 2010 and 2019 were oncology treatments, a strong indicator for PCI that oncology will continue to be a key focus for the industry in the coming years, the company said.
Since the United Arab Emirates sovereign fund Mubadala and private equity firm Kohlberg & Company took big stakes in PCI about two years ago, the company has been on an expansion tear that has included its sites in Berlin; Melbourne, Australia; San Diego; and Rockford, Illinois. In February, the company announced upgrades for its San Diego and Melbourne plants.